Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
About BioCorRx Inc. (BICX)
BioCorRx Inc. (OTCQB: BICX) is a pioneering healthcare solutions company dedicated to addressing the critical public health challenges of addiction and obesity through innovative treatment programs and clinical-stage pharmaceutical development. Headquartered in Anaheim, California, BioCorRx operates at the intersection of addiction treatment, behavioral health, and pharmaceutical innovation, offering a comprehensive suite of solutions aimed at improving patient outcomes and quality of life.
Core Business Areas
BioCorRx’s business is centered on two primary domains:
- Substance Use Disorder (SUD) Treatment: The company’s flagship offering, the BioCorRx® Recovery Program, combines a proprietary long-acting naltrexone implant with cognitive behavioral therapy (CBT) modules and peer support. This program is designed to significantly reduce cravings for alcohol and opioids, addressing the root causes of addiction while providing patients with the tools and support needed for sustainable recovery.
- Weight Loss Solutions: The UnCraveRx® Weight Loss Program incorporates medication-assisted therapy with behavioral and nutritional counseling, offering a holistic approach to combating obesity. This program leverages the company’s expertise in addiction treatment to address the behavioral aspects of weight management.
Pharmaceutical Innovation
Through its majority-owned subsidiary, BioCorRx Pharmaceuticals Inc., the company is advancing clinical-stage drug development with a focus on implantable, long-acting naltrexone therapies. The flagship product under development, BICX104, is a biodegradable naltrexone pellet designed for subcutaneous implantation. This innovative treatment aims to improve patient compliance by providing sustained therapeutic levels of naltrexone for up to 84 days, significantly reducing the risk of relapse in opioid and alcohol use disorders. BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA) under the NIH HEAL Initiative®, further underscoring the company’s commitment to addressing the opioid crisis.
Market Position and Differentiation
BioCorRx operates in a competitive landscape that includes traditional rehabilitation centers, pharmaceutical companies, and behavioral health providers. The company sets itself apart through its integrated approach, which combines FDA-approved medications, proprietary delivery systems, and evidence-based behavioral therapies. Its focus on long-acting, implantable treatments addresses common challenges in addiction recovery, such as medication adherence and patient compliance, offering a unique value proposition in the market.
Strategic Partnerships and Funding
BioCorRx has secured significant funding and partnerships to advance its mission. Notably, the company received a multi-year grant from NIDA to accelerate the development of BICX104 for methamphetamine use disorder (MUD), a condition with no currently approved medications. This collaboration highlights BioCorRx’s role as a trusted partner in addressing unmet medical needs and its ability to leverage external resources to drive innovation.
Commitment to Public Health
Beyond its commercial pursuits, BioCorRx is deeply committed to tackling pressing public health issues. Its programs are designed not only to treat addiction and obesity but also to alleviate the broader societal impacts of these conditions, such as healthcare costs, lost productivity, and the emotional toll on families and communities.
Future Outlook
With a robust pipeline of innovative treatments, a growing intellectual property portfolio, and strategic collaborations with leading institutions, BioCorRx is well-positioned to make a lasting impact on the fields of addiction treatment and behavioral health. The company’s ongoing efforts to secure FDA approval for BICX104 and expand its weight loss program reflect its commitment to addressing unmet medical needs and improving patient outcomes worldwide.
BioCorRx Inc. (OTCQB:BICX) will present at the Planet MicroCap Showcase 2022 on May 4, 2022, at Bally's Hotel & Casino, Las Vegas. The presentation, hosted by CEO Lourdes Felix and President Brady Granier, will start at 3:00 PM PT / 6:00 PM ET. Interested investors can register for 1x1 meetings during the conference. A webcast of the presentation will also be available. BioCorRx focuses on innovative addiction treatment solutions and is developing BICX104, an implantable naltrexone pellet aimed at treating alcohol and opioid use disorders.
BioCorRx Inc. (OTCQB: BICX) announced the receipt of a $100,000 supplemental grant from the National Institute on Drug Abuse for the first-in-human clinical trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder. This grant contributes to the nearly $9.3 million in non-dilutive funding received from NIH/NIDA. BICX104 benefits from active Investigational New Drug status and a favorable FDA review pathway. The funding will enhance data sharing and support further clinical development of the medication.
BioCorRx (BICX) provided a 2021 year-end business update highlighting several key milestones. The company received FDA clearance for human trials of BICX104, an implantable pellet targeting opioid use disorder. A major achievement included a $3.5 million grant from NIDA, contributing to nearly $9.2 million in non-dilutive funding. Furthermore, intellectual property expansion includes a patent acquisition and a newly filed patent application for BICX104. The company is set to begin first-in-human trials in Q2 2022, aiming for improved compliance and outcomes in treating opioid use disorder.
BioCorRx Inc. (OTCQB: BICX) has announced its participation in two significant conferences: the 2022 Virtual Growth Conference from March 28-30 and the ASAM 53rd Annual Conference from March 31 to April 3. The Virtual Growth Conference, hosted by Maxim Group LLC, features various presentations and discussions aimed at fostering growth. Meanwhile, the ASAM conference in Hollywood, FL, will showcase advancements in addiction medicine, where BioCorRx Pharmaceuticals will exhibit at booth 306. The company specializes in innovative substance abuse treatment programs.
BioCorRx Inc. (OTCQB: BICX) has received Independent Institutional Review Board (IRB) approval for its Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This approval is a significant milestone, allowing the company to initiate first-in-human trials. The trial, involving 24 healthy volunteers, will compare BICX104 to marketed naltrexone injections. The company is collaborating with the National Institute on Drug Abuse and aims to enhance patient compliance to naltrexone therapy, potentially improving outcomes in addiction treatment.
BioCorRx Inc. (OTCQB: BICX) announced the completion of a clinical trial agreement with Orange County Research Center for its first-in-human trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This collaboration, led by Dr. Joel M. Neutel, signifies a major milestone for BioCorRx, as they seek FDA approval for the pellet. The trial is expected to commence once clinical samples are ready and participants are recruited. BICX104 is being developed with the National Institute on Drug Abuse, providing potential dual indications for OUD and Alcohol Use Disorder.
BioCorRx Inc. (OTCQB: BICX) announced that CEO Lourdes Felix and President Brady Granier will present at the H.C. Wainwright BioConnect 2022 Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand starting January 10, 2022, at 7:00 AM ET. BioCorRx is focused on innovative treatment solutions for substance abuse, including the Beat Addiction Recovery program and the UnCraveRx® Weight Loss Program. The company also seeks FDA approval for BICX104, an implantable naltrexone pellet for treating alcohol and opioid use disorders.
BioCorRx Inc. (OTCQB: BICX) has appointed Dr. Jie Shen to its Scientific Advisory Board (SAB). Dr. Shen brings expertise in drug delivery systems and has previously worked on formulations for naltrexone, crucial for advancing BICX104, an implantable naltrexone pellet aimed at treating opioid use disorder. CEO Lourdes Felix emphasized the significance of Dr. Shen’s experience in enhancing BioCorRx's capabilities as it progresses towards human trials. BioCorRx is focused on innovative addiction treatment solutions and currently seeks FDA approval for BICX104.
BioCorRx Inc. (OTCQB: BICX) announced that CEO Lourdes Felix and President Brady Granier will present at the Benzinga All Access event on December 2, 2021, at 11:00 A.M. Eastern Time. The event will be streamed live, and an archived recording will be available on the company's investor relations website. BioCorRx specializes in innovative treatment programs for substance abuse, including the Beat Addiction Recovery program and the UnCraveRx® Weight Loss Program. The company is also developing BICX104, an implantable naltrexone pellet aimed at treating alcohol and opioid use disorders.
BioCorRx Inc. (OTCQB: BICX) announced the acquisition of a patent application from Calista Therapeutics covering a solid implant formulation for drug delivery. This patent, application number 17/465,748, may enhance current naltrexone formulations and is expected to add value to BioCorRx's existing intellectual property portfolio. CEO Lourdes Felix expressed excitement over the potential improvements in drug delivery systems, which could benefit the company’s treatment programs for substance abuse and related disorders.
FAQ
What is the current stock price of Biocorrx (BICX)?
What is the market cap of Biocorrx (BICX)?
What does BioCorRx Inc. specialize in?
What is the BioCorRx Recovery Program?
What is BICX104?
How does BioCorRx address obesity?
What makes BioCorRx unique in the addiction treatment market?
What partnerships has BioCorRx formed to advance its treatments?
What challenges does BioCorRx aim to address in addiction treatment?
Does BioCorRx have any patented technologies?
What is the significance of the NIH HEAL Initiative® for BioCorRx?
How does BioCorRx contribute to public health?
